The periodical about the pharmaceutical and medical equipment markets
(Russian pharmacies) - specialized periodical edition for pgarmacy professionals
Medical Council - Scientific Journal for Physicians
Up to 10 domestic and leading global drugmakers operating in the Russian market are considering reducing prices for their drugs, and in particular those intended for the treatment of the most serious diseases, including HIV/AIDS, hepatitis C, tuberculosis and some others.
CPhI Russia @IPhEB returns to the Russian capital – taking place at the JSC VDNH (VVC), Moscow from March 28 to 30 – as the Government’s Pharma 2020 plan continues to stimulate demand for international pharmaceutical ingredients, manufacturing and packaging equipment.
The Russian government is ready to allow the production of anti-HIV drugs bypassing patents of their right-holders.
The Russian Ministry of Health (MoH) has awarded domestic biotech firm Biocad marketing authorization for its interferon beta-1a biosimilar, a knockoff of Merck KGaA's (MRK: DE) Biogen’s Rebif that is a key component in treatment of relapsing-remitting multiple sclerosis (RRMS) and included in all international recommendations and protocols.
1 - 5 из 882
The pharmaceutical market in Russia is one of the fastest growing globally and is set to rise from $20.91 billion in 2016 to $38.56 billion by 2021, representing a compound annual growth rate of 13%, according to research and consulting firm GlobalData.
Начало | Пред. |
programmer of electronic software products